| 摘要: |
| 文章通过文献和报道对羟乙基淀粉系列原料的分类、临床不良反应关联关键质量指标的控制、研究情况进行简述,并强调羟乙基淀粉系列原料药质量标准统一的重要性。 |
| 关键词: 羟乙基淀粉系列原料 不良反应 质量标准 |
| DOI:10.13506/j.cnki.jpr.2016.12.015 |
| 基金项目: |
|
|
|
| Discussion on the control of Hydroxyethyl starch series raw material quality |
| QI Lin1,2,CHEN Renping1,LIAN Chuanbao3,YIN Jianfeng4 |
| (1.Shandong Qidu Pharmaceutical Co.,Ltd.,Linzi 255400,China;2.Shandong Provincial Key Laboratory of Neuroprotective Drugs,Zibo 255400,China;3.Zibo Food and Drug Administration, Zibo 255400,China;4.Zibo Linzi Food and Drug Administration,Linzi 255400,China) |
| Abstract: |
| This paper briefly described the classification of a series of hydroxyethyl starch APIs,clinical adverse reactions associated with key indicators of quality control and research situations according to the literature and reports.Moreover,it emphasized the importance of unified quality standards of a series of hydroxyethyl starch APIs. |
| Key words: Hydroxyethyl starch APIs Adverse reactions Quality standards |